Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006-July 2012

L. B. Wright; G. J. Hughes; K. E. Chapman; Russell Gorton; D. Wilson

doi:10.1016/j.trivac.2013.09.004

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006-July 2012

L. B. Wright^*, G. J. Hughes, K. E. Chapman, Russell Gorton, D. Wilson

^*Corresponding author for this work

Field Epidemiology (YH)

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for all aged ≥65 years in the UK to help reduce the burden of invasive pneumococcal disease (IPD). A total of 728 IPD cases aged ≥65 years were diagnosed between 1 April 2006 and 31 July 2012 in the North East of England. Crude vaccine effectiveness (VE) estimates for PPV23 were calculated using the indirect-cohort method using a stratified analysis. VE for persons aged ≥65 years was 28.5% (95% confidence interval: -17.4%, 56.5%). PPV23 was less effective in older age groups at IPD diagnosis and for those vaccinated at an older age. Estimates of VE published since the introduction of PPV23 appear to show a decrease in VE over time, possibly due to changes in demographics, circulating serotypes and vaccine formulation. An effective PPV23 vaccination programme should continue in those aged ≥65 years in the North East of England.

Original language	English
Pages (from-to)	45-48
Number of pages	4
Journal	Trials in Vaccinology
Volume	2
Issue number	1
DOIs	https://doi.org/10.1016/j.trivac.2013.09.004
Publication status	Published - 2013

Bibliographical note

Funding Information:
This work was supported by a grant from the Health Protection Agency Strategic Research and Development Fund between April 2009 and March 2012; and an unrestricted educational grant from Sanofi Pasteur MSD (UK12C1036) from April 2012.

Keywords

23-Valent pneumococcal polysaccharide vaccine
Aged ≥65 years
Invasive pneumococcal disease
North East England
Vaccine effectiveness

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trivac.2013.09.004

Cite this

@article{ce6e391b7aaf46ed97aca70761f2897b,

title = "Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006-July 2012",

abstract = "The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for all aged ≥65 years in the UK to help reduce the burden of invasive pneumococcal disease (IPD). A total of 728 IPD cases aged ≥65 years were diagnosed between 1 April 2006 and 31 July 2012 in the North East of England. Crude vaccine effectiveness (VE) estimates for PPV23 were calculated using the indirect-cohort method using a stratified analysis. VE for persons aged ≥65 years was 28.5% (95% confidence interval: -17.4%, 56.5%). PPV23 was less effective in older age groups at IPD diagnosis and for those vaccinated at an older age. Estimates of VE published since the introduction of PPV23 appear to show a decrease in VE over time, possibly due to changes in demographics, circulating serotypes and vaccine formulation. An effective PPV23 vaccination programme should continue in those aged ≥65 years in the North East of England.",

keywords = "23-Valent pneumococcal polysaccharide vaccine, Aged ≥65 years, Invasive pneumococcal disease, North East England, Vaccine effectiveness",

author = "Wright, {L. B.} and Hughes, {G. J.} and Chapman, {K. E.} and Russell Gorton and D. Wilson",

note = "Funding Information: This work was supported by a grant from the Health Protection Agency Strategic Research and Development Fund between April 2009 and March 2012; and an unrestricted educational grant from Sanofi Pasteur MSD (UK12C1036) from April 2012. ",

year = "2013",

doi = "10.1016/j.trivac.2013.09.004",

language = "English",

volume = "2",

pages = "45--48",

journal = "Trials in Vaccinology",

issn = "1879-4378",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006-July 2012

AU - Wright, L. B.

AU - Hughes, G. J.

AU - Chapman, K. E.

AU - Gorton, Russell

AU - Wilson, D.

N1 - Funding Information: This work was supported by a grant from the Health Protection Agency Strategic Research and Development Fund between April 2009 and March 2012; and an unrestricted educational grant from Sanofi Pasteur MSD (UK12C1036) from April 2012.

PY - 2013

Y1 - 2013

N2 - The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for all aged ≥65 years in the UK to help reduce the burden of invasive pneumococcal disease (IPD). A total of 728 IPD cases aged ≥65 years were diagnosed between 1 April 2006 and 31 July 2012 in the North East of England. Crude vaccine effectiveness (VE) estimates for PPV23 were calculated using the indirect-cohort method using a stratified analysis. VE for persons aged ≥65 years was 28.5% (95% confidence interval: -17.4%, 56.5%). PPV23 was less effective in older age groups at IPD diagnosis and for those vaccinated at an older age. Estimates of VE published since the introduction of PPV23 appear to show a decrease in VE over time, possibly due to changes in demographics, circulating serotypes and vaccine formulation. An effective PPV23 vaccination programme should continue in those aged ≥65 years in the North East of England.

AB - The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for all aged ≥65 years in the UK to help reduce the burden of invasive pneumococcal disease (IPD). A total of 728 IPD cases aged ≥65 years were diagnosed between 1 April 2006 and 31 July 2012 in the North East of England. Crude vaccine effectiveness (VE) estimates for PPV23 were calculated using the indirect-cohort method using a stratified analysis. VE for persons aged ≥65 years was 28.5% (95% confidence interval: -17.4%, 56.5%). PPV23 was less effective in older age groups at IPD diagnosis and for those vaccinated at an older age. Estimates of VE published since the introduction of PPV23 appear to show a decrease in VE over time, possibly due to changes in demographics, circulating serotypes and vaccine formulation. An effective PPV23 vaccination programme should continue in those aged ≥65 years in the North East of England.

KW - 23-Valent pneumococcal polysaccharide vaccine

KW - Aged ≥65 years

KW - Invasive pneumococcal disease

KW - North East England

KW - Vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=84889080843&partnerID=8YFLogxK

U2 - 10.1016/j.trivac.2013.09.004

DO - 10.1016/j.trivac.2013.09.004

M3 - Article

AN - SCOPUS:84889080843

SN - 1879-4378

VL - 2

SP - 45

EP - 48

JO - Trials in Vaccinology

JF - Trials in Vaccinology

IS - 1

ER -

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006-July 2012

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this